约 4 个结果
在新选项卡中打开链接
Are We Reaching the End for Endocrine-Disrupting Chemicals?
2024年6月12日 · The world is waking up to plastic pollution's impact on health as well as the environment, and a global treaty to end it is in the works.
First Oral PCSK9 Shows Promise Lowering Cholesterol - Medscape
2024年6月28日 · AZD0780 — the first oral PCSK9 inhibitor — is lowering LDL cholesterol levels, report phase 1 trial investigators, but specialists are questioning the early findings.
FDA Approves Dapagliflozin (Farxiga) for Type 2 Diabetes
2014年1月8日 · FDA Requiring Several Postmarketing Studies. Dapagliflozin's safety and effectiveness were evaluated in 16 clinical trials involving more than 9400 patients with type 2 …
Combination Therapy in the Treatment of Alzheimer's Disease
AZD-1446: Nicotinic α4β2-receptor activator 203: II 202: No cognitive or global benefits in AD 204: EVP-6124: Selective nicotinic α7-receptor agonist 123,132: II 123,132,202: